What “not FDA-approved” means for a compounded drug
Every page on this site that discusses personalized compounded semaglutide or tirzepatide says the same thing: these medications are not FDA-approved and are not equivalent to FDA-approved products. This guide explains what that sentence means in practice, because it is the single most important fact about compounded treatment and it is easy to read past.
When the FDA approves a drug, the manufacturer has submitted evidence from clinical trials of that specific product, in that specific formulation, and the agency has reviewed it for safety and effectiveness. The manufacturing is also reviewed. A compounded drug has not been through any of that. The FDA’s human drug compounding page states that compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed. Its compounding questions and answers page adds the reason it matters: poor compounding practices can result in serious drug quality problems, such as contamination or a drug that contains too much or too little active ingredient, which can lead to serious patient injury and death.
The FDA has also spoken specifically about GLP-1 medications. Its statement on concerns with unapproved GLP-1 drugs used for weight loss, dated September 1, 2026, reports that the agency has received reports of adverse events, some requiring hospitalization, that may be related to dosing errors with personalized compounded semaglutide, including patients measuring and self-administering incorrect doses and providers miscalculating doses. It warns that some compounded products have used salt forms of semaglutide, sodium and acetate, which differ from the active ingredient in the approved products and for which the FDA has no safety data. And it counts the reports it has received: as of May 31, 2026, 990 adverse event reports associated with personalized compounded semaglutide and more than 730 associated with personalized compounded tirzepatide.
None of that means a compounded medication is unsafe for you. It means that the assurance an approved product carries is absent, and that the assurance has to come from somewhere else: from the pharmacy’s licensure and practice, from the provider’s judgment, and from you following the plan you are given. The rest of this guide is about those three things.
How 503A pharmacies are regulated
Compounding is legal and regulated, and the regulation has a specific shape. According to the FDA’s compounding questions and answers, state-licensed pharmacies that are not registered with the FDA as outsourcing facilities, the 503A pharmacies, are overseen day to day by state boards of pharmacy. Facilities that register as outsourcing facilities under section 503B are primarily overseen and inspected by the FDA and must follow current good manufacturing practice requirements, which 503A pharmacies are not required to follow.
A 503A pharmacy compounds for an identified individual patient on the basis of a prescription. That patient-specific prescription is the legal foundation of the practice, and it is why a legitimate compounded GLP-1 medication cannot be bought without a prescription from a licensed prescriber who has evaluated you.
Bodi Envi publishes its own statement of how this applies to its programs: applicable state boards of pharmacy regulate and inspect 503A compounding pharmacies, and pharmacy operations and sterile compounding practices are subject to applicable U.S. Pharmacopeia standards. The FDA’s advice on buying GLP-1 medications safely points the same way. Its concerns statement tells patients to obtain a prescription from a licensed healthcare provider and to fill it only at a state-licensed pharmacy, and it directs people to its BeSafeRx resources on buying medication online.
What Bodi Envi does and does not do
Bodi Envi is a LegitScript-certified U.S. telehealth platform that connects eligible adults with licensed healthcare providers for personalized medical weight-management care. It is not a medical practice, pharmacy or medication manufacturer. It does not prescribe, does not dispense and does not compound.
Clinical services for applicable Bodi Envi programs are provided by Wasef Health, PC, whose licensed providers independently evaluate patients and determine whether treatment is medically appropriate. Prescriptions, when a provider writes one, are dispensed and fulfilled by third party U.S. 503A licensed compounding pharmacies. VialsRx is the current pharmacy partner for applicable GLP-1 prescriptions, and pharmacy availability may vary by program and patient location. Treatment is not guaranteed, and completing an assessment or paying for a program does not guarantee a prescription.
LegitScript certification is a statement about the platform, not about any medication. LegitScript’s healthcare certification page sets out the standards a certified merchant must meet. They include being adequately licensed for the services offered and in the jurisdictions served, complying with applicable laws and regulations, disclosing any prior criminal, regulatory or civil violations, holding affiliates and partners to the same standards, disclosing the jurisdictions served, complying with privacy law, dispensing prescription drugs only on receipt of a valid prescription, keeping all practices and offers accurate and transparent, and advertising in accordance with applicable law. Bodi Envi’s certification can be verified through the LegitScript badge in the footer of every page. Certification does not make a compounded medication FDA-approved, and Bodi Envi does not claim that it does.
Common side effects per the labels of brand name versions
The most reliable published description of what these medications do to people comes from the FDA-approved prescribing information for the branded products, which report what happened in their clinical trials. Two things to keep in mind: the figures describe Wegovy® and Zepbound®, not compounded versions, and the two labels come from different trials and cannot be compared directly with each other.
The Wegovy® label reports, among adults treated for weight reduction at the 2.4 mg dose, nausea in 44 percent of patients against 16 percent on placebo, diarrhea in 30 percent against 16 percent, vomiting in 24 percent against 6 percent, constipation in 24 percent against 11 percent, abdominal pain in 20 percent against 10 percent, headache in 14 percent against 10 percent, fatigue in 11 percent against 5 percent, dyspepsia in 9 percent against 3 percent and dizziness in 8 percent against 4 percent.
The Zepbound® label reports, across its two pooled weight reduction studies, nausea in 25 to 29 percent of patients, diarrhea in 19 to 23 percent, vomiting in 8 to 13 percent, constipation in 11 to 17 percent, abdominal pain and dyspepsia in 9 to 10 percent each, injection site reactions in 6 to 8 percent and fatigue in 5 to 7 percent.
Both labels say the escalation schedule exists to reduce gastrointestinal side effects, and both allow a provider to slow the escalation if a dose is not tolerated. If side effects are affecting you, that is exactly the kind of thing to raise with your provider through the portal rather than to push through or to fix by changing your own dose. The studies above were on brand name versions of semaglutide and tirzepatide. These studies cannot be used to compare to personalized compounded versions, which are different from the brand name product. This information is for educational purposes only.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Serious warnings per the labels
Both prescribing information documents open with a boxed warning, the strongest warning the FDA requires on a label, and both carry a list of warnings and precautions. Each is stated here as the label states it.
Thyroid C-cell tumours. The Wegovy® label states that in rodents semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumours at clinically relevant exposures, and that it is unknown whether Wegovy® causes thyroid C-cell tumours, including medullary thyroid carcinoma, in humans. The Zepbound® label states the same for tirzepatide in rats. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and both tell patients to report a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath.
Acute pancreatitis. Both labels warn that pancreatitis has been reported and direct that the medication be discontinued if pancreatitis is suspected.
Acute gallbladder disease. Both labels warn of gallbladder events, including gallstones, and advise investigation if they are suspected.
Hypoglycaemia. Both labels warn that the risk of low blood sugar is increased when the medication is used with insulin or an insulin secretagogue such as a sulfonylurea, and the Wegovy® label notes that hypoglycaemia was reported more often with the medication than with placebo in patients with type 2 diabetes.
Acute kidney injury. Both labels warn of kidney injury linked to dehydration from nausea, vomiting and diarrhea, and advise monitoring in patients with kidney impairment.
Severe gastrointestinal reactions. Both labels warn of severe gastrointestinal adverse reactions and advise against use in patients with severe gastroparesis.
Hypersensitivity. Both labels warn of serious hypersensitivity reactions including anaphylaxis and angioedema, and a known serious hypersensitivity to the medication is a contraindication.
Diabetic retinopathy. Both labels warn of diabetic retinopathy complications in patients with type 2 diabetes, and advise monitoring in patients with a history of it.
Other warnings. The Wegovy® label also warns of an increase in resting heart rate. Both labels warn of the risk of pulmonary aspiration during general anesthesia or deep sedation, and both direct that pens must never be shared between patients.
Compounded medications carry no label of their own from the FDA, which is why this guide reports the branded labels: they are the closest published description of the active ingredient’s known risks.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Who should not take these medications
The labels answer this in two parts. The contraindications, where the medication must not be used, are a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a known serious hypersensitivity to the medication or any of its excipients.
The warnings are the second part, and they are where a provider’s judgment comes in. A history of pancreatitis, gallbladder disease, kidney impairment or diabetic retinopathy, current use of insulin or a sulfonylurea, and a planned procedure under anesthesia are all things the label tells a prescriber to weigh. So is pregnancy, which the labels address separately and which you should raise with your provider directly if it applies or could apply to you.
Bodi Envi’s online assessment asks about all of this because the provider cannot decide safely without it. Answer it completely and truthfully. A licensed healthcare provider determines whether treatment is appropriate for each individual patient, and if the answer is no, that is the system working.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
How to reduce risk
Most of what you can do to lower your own risk follows from the sections above.
Get your prescription from a licensed provider who has evaluated you, and have it filled only by a state-licensed pharmacy. That is the FDA’s own advice on unapproved GLP-1 drugs, and it is how Bodi Envi’s programs are structured.
Follow the dosing plan you are given, exactly. The FDA’s concerns statement links reported hospitalizations to dosing errors with personalized compounded semaglutide, including patients drawing up the wrong volume. A compounded vial does not come with a pen that sets the dose for you. Use the measuring instructions from the pharmacy, ask your care team if anything is unclear, and never adjust your dose on your own.
Do not use medication that arrives warm or that has been frozen. The FDA advises against using any injectable GLP-1 drug that arrives warm, and both branded labels say not to use the product if it has been frozen.
Report side effects. Tell your provider through the portal about anything persistent, and seek emergency care for anything severe. The FDA asks patients and healthcare professionals to report problems with any medical product, including compounded drugs, to MedWatch, its safety information and adverse event reporting program.
Keep your provider informed of changes: a new medication, a new diagnosis, a planned surgery, a pregnancy. Each of those can change whether treatment is still appropriate.
Storage and handling
Storage instructions for a compounded medication come from the pharmacy that prepared it, on the label attached to your vial, and those instructions are the ones to follow. For reference, the branded labels describe similar rules. The Wegovy® label says to store the single-dose pen in the refrigerator between 36°F and 46°F, that it may be kept between 46°F and 86°F in its original carton for up to 28 days before use, and that it must not be frozen and should be protected from light. The Zepbound® label says to store the single-dose pen or vial in the refrigerator between 36°F and 46°F, that it may be kept unrefrigerated at up to 86°F for up to 21 days, and that it must not be frozen and should be protected from heat and light. If your medication arrives warm, or you are unsure whether it has been stored correctly, contact the pharmacy before using it.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.